Therefore, serum EphA2-NF, as a new biomarker for pancreatic cancer diagnosis independent of CA19-9, may improve the diagnostic accuracy in patients with Lewis-negative pancreatic cancer combined with imaging tests. Here, EPHA2 is linked to familial pancreatic carcinoma.